Now that 2022 is in the books, it is safe to say investors won't remember it fondly. The economy and the market suffered throughout last year, severely affecting businesses worldwide and dragging down even quality stocks. Amid these troubles, some corporations managed to perform much better than most.

Biotech giant Gilead Sciences (NASDAQ: GILD) and payment technology specialist Visa (NYSE: V) were among them. Moreover, these two companies have the tools to deliver market-beating returns again.

Gilead Sciences ended 2022 on a positive note. On Dec. 22, the drugmaker announced that the U.S. Food and Drug Administration (FDA) had approved Sunlenca, a long-acting HIV treatment option. Sunlenca is the first twice-a-year HIV regimen to make it past regulatory agencies. It was also granted approval in Europe in August. 

Continue reading

Source Fool.com